Isocitrate Dehydrogenase (IDH) Inhibitors Market Report 2026

The isocitrate dehydrogenase (idh) inhibitors market size has grown exponentially in recent years. It will grow from $2.46 billion in 2025 to $3.13 billion in 2026 at a compound annual growth rate (CAGR) of 26.8%. The growth in the historic period can be attributed to cancer genomics research, unmet oncology needs, mutation-driven drug discovery, hospital oncology adoption, clinical trial expansion.

The isocitrate dehydrogenase (idh) inhibitors market size is expected to see exponential growth in the next few years. It will grow to $8.02 billion in 2030 at a compound annual growth rate (CAGR) of 26.6%. The growth in the forecast period can be attributed to precision medicine advancement, biomarker-driven oncology care, rare cancer drug pipelines, combination cancer therapies, regulatory support for targeted drugs. Major trends in the forecast period include expansion of targeted oncology therapies, increased genetic mutation-based drug development, growing focus on rare cancer treatment, rising use of precision oncology diagnostics, advancement of small molecule cancer inhibitors.

The rising incidence of acute myeloid leukemia (AML) is expected to drive growth in the isocitrate dehydrogenase (IDH) inhibitors market in the coming years. AML is a fast-growing blood and bone marrow cancer characterized by the rapid production of abnormal white blood cells that interfere with normal blood cell formation. The increasing occurrence of AML is largely due to the aging population, as older adults are at higher risk of developing this aggressive blood cancer because of age-related changes in bone marrow and immune function. IDH inhibitors help treat AML by blocking mutant IDH enzymes, which restores normal blood cell development and slows the proliferation of leukemia cells. For example, according to the Leukaemia Foundation in February 2023, between 2022 and 2035, over 7,000 children, 6,000 young adults, and 108,000 adults aged 25-65 are expected to be diagnosed with blood cancers, primarily acute lymphoblastic leukemia (ALL), AML, and non-Hodgkin lymphoma (NHL). As a result, the rising frequency of AML is expected to drive growth in the IDH inhibitors market.

Leading companies in the IDH inhibitors market are focusing on securing regulatory approvals to expand clinical use, accelerate market entry, and gain a competitive edge in treating IDH-mutant cancers. Regulatory approvals are official permissions granted by health authorities that allow a drug to be marketed and used after its safety and efficacy have been confirmed. For instance, in August 2024, Servier Laboratoires, a France-based pharmaceutical company, received FDA approval for VORANIGO (vorasidenib) tablets as the first targeted therapy for patients with Grade 2 IDH-mutant glioma, including astrocytoma and oligodendroglioma with IDH1 or IDH2 mutations. This oral treatment significantly improved progression-free survival, as demonstrated in the Phase 3 INDIGO trial, where patients had a median progression-free survival of 27.7 months compared to 11.1 months for placebo. VORANIGO provides a convenient, well-tolerated treatment option with manageable side effects, representing a major advance for patients with limited prior therapies.

In November 2025, Amoy Diagnostics Co. Ltd., a China-based healthcare technology company, partnered with Servier to expand precision oncology and genetic testing solutions. Through this collaboration, Amoy Diagnostics and Servier aim to enhance cancer and rare disease diagnostics by combining Amoy’s molecular assays with Servier’s clinical genomics and therapeutic expertise. The partnership seeks to deliver faster, more accurate, and widely accessible testing, improve data interpretation, streamline laboratory workflows, and increase patient access to personalized medicine. Servier is a France-based healthcare technology company specializing in the development and commercialization of innovative therapeutics and diagnostic solutions across oncology, cardiology, and rare diseases.

Major companies operating in the isocitrate dehydrogenase (idh) inhibitors market are Roche Holding AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Daiichi Sankyo Company Limited, Les Laboratoires Servier, Evotec SE, HUTCHMED (China) Limited, Rigel Pharmaceuticals Inc., CStone Pharmaceuticals, Forma Therapeutics Holdings Inc., Philogen S.p.A., Kura Oncology Inc., Agios Pharmaceuticals Inc., Adooq Bioscience LLC, Taiho Pharmaceutical Co. Ltd., Celgene Corporation, Focus Biomolecules LLC, InvivoChem LLC.

North America was the largest region in the isocitrate dehydrogenase (IDH) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the isocitrate dehydrogenase (idh) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the isocitrate dehydrogenase (idh) inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the IDH inhibitors market by increasing the cost of specialty APIs, oncology-grade excipients, and advanced drug-delivery materials. Oral and parenteral targeted therapies for AML, glioma, and cholangiocarcinoma are most affected, particularly in North America and Europe due to dependence on imported oncology drug ingredients. Hospitals and specialty oncology centers face higher therapy costs. However, tariffs are encouraging local synthesis of small-molecule oncology drugs and strengthening regional pharmaceutical research and manufacturing capacity.

The isocitrate dehydrogenase (idh) inhibitors market research report is one of a series of new reports that provides isocitrate dehydrogenase (idh) inhibitors market statistics, including isocitrate dehydrogenase (idh) inhibitors industry global market size, regional shares, competitors with a isocitrate dehydrogenase (idh) inhibitors market share, detailed isocitrate dehydrogenase (idh) inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the isocitrate dehydrogenase (idh) inhibitors industry. This isocitrate dehydrogenase (idh) inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Isocitrate dehydrogenase (IDH) inhibitors are a class of targeted cancer therapies designed to block the activity of mutated IDH1 and IDH2 enzymes. These enzymes play a role in cellular metabolism, and mutations can lead to abnormal cell growth and cancer development.

The main types of IDH inhibitors include those targeting IDH1 mutant medullary malignant tumors, IDH2 mutant medullary malignant tumors, and others. IDH1 mutant medullary malignant tumors are cancers that arise in the central (medullary) part of an organ or tissue and are associated with mutations in the IDH1 gene. Treatment involves molecules such as monoclonal antibodies, peptides, small molecules, and others, administered via oral, parenteral, subcutaneous, or topical routes. They are applied in therapies including FLT3 inhibitors, DH inhibitors, hedgehog pathway inhibitors, and related treatments.

The isocitrate dehydrogenase (IDH) inhibitors market consists of sales of selective IDH1 inhibitors, selective IDH2 inhibitors, dual IDH1/IDH2 inhibitors, combination therapies, and delivery forms. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods, such as formulation development, packaging, and regulatory support.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.